Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
NEW YORK, Oct. 11, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between December 16, 2015 and September 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/spectrum-pharmaceuticals-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the “FDA”) questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants’ public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/spectrum-pharmaceuticals-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
